| Letter | 2024 | Monocytosis as prognostic factor for chronic graft versus host disease | BONE MARROW TRANSPLANTATION |
| Artículo | 2024 | Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial | BONE MARROW TRANSPLANTATION |
| Letter | 2024 | Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT | BONE MARROW TRANSPLANTATION |
| Letter | 2024 | Standardized translations of the Lee Chronic GvHD Symptom Scale to 12 European languages: an EU COST Action cGvHD Eurograft project | BONE MARROW TRANSPLANTATION |
| Artículo | 2024 | Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT | BONE MARROW TRANSPLANTATION |
| Corrección | 2024 | Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry-based study from the Chronic Malignancies Working Party of the EBMT (Mar, 10.1038/s41409-024-02269-4, 2024) | BONE MARROW TRANSPLANTATION |
| Artículo | 2023 | Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT | BONE MARROW TRANSPLANTATION |
| Letter | 2023 | Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV) | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2022 | Overall survival in advanced stage mantle cell lymphoma after early autologous stem cell transplantation with cisplatin, etoposide, cytarabine and melphalan (peam) as a conditioning regimen | BONE MARROW TRANSPLANTATION |
| Artículo | 2021 | Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study | BONE MARROW TRANSPLANTATION |
| Artículo | 2021 | Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment | BONE MARROW TRANSPLANTATION |
| Artículo | 2021 | Delayed administration of ixazomib modifies the immune response and prevents chronic graft-versus-host disease. | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2021 | Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplantation: A Retrospective Analysis | BONE MARROW TRANSPLANTATION |
| Artículo | 2021 | Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT | BONE MARROW TRANSPLANTATION |
| Letter | 2021 | Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors | BONE MARROW TRANSPLANTATION |
| Artículo | 2021 | Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT | BONE MARROW TRANSPLANTATION |
| Artículo | 2020 | Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation | BONE MARROW TRANSPLANTATION |
| Artículo | 2020 | Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party | BONE MARROW TRANSPLANTATION |
| Artículo | 2020 | Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation | BONE MARROW TRANSPLANTATION |
| Artículo | 2020 | Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2019 | Safety and efficacy of the BCR inhibitors after allogeneic stem cell transplantation for CLL | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2018 | European Myeloma Network phase I trial on RIC allogeneic transplantation: an optimized program for high risk relapsed myeloma patients | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2018 | Hematopoietic Stem cell transplant in Aplastic anemia in patients older than 40 years: the experience of the Spanish Group of Hematopoietic Stem Cell Transplant (GETH) | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2017 | Immunomodulatory effect of polyphenols obtained from olive oil in acute graft versus host disease | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2017 | Improvement of outcome after autologous stem cell transplantation by reduction of infections and SOS/VOD syndrome's related mortality: 28 years single-center experience | BONE MARROW TRANSPLANTATION |
| Artículo | 2017 | Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation | BONE MARROW TRANSPLANTATION |
| Artículo | 2017 | Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2016 | A novel genetic and clinical predictive model for severe acute and chronic graft versus host disease after identical HLA-allogeneic stem-cell transplantation | BONE MARROW TRANSPLANTATION |
| Letter | 2016 | Differences in stem cell transplantation activity among regions in Spain: an economic explanation | BONE MARROW TRANSPLANTATION |
| Letter | 2016 | GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2016 | Multicenter and Retrospective study for Risk factors affecting DLCOc prior Allogeneic Hematopoietic Stem Cell Transplant | BONE MARROW TRANSPLANTATION |
| Letter | 2016 | Pre-transplant diastolic but not systolic dysfunction has a negative prognostic impact after allogeneic stem cell transplantation | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2015 | Analysis of factors affecting pre transplant pulmonary function tests and impact on overall Survival after allogeneic stem cell transplantation | BONE MARROW TRANSPLANTATION |
| Artículo | 2015 | Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time | BONE MARROW TRANSPLANTATION |
| Artículo | 2015 | GVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT | BONE MARROW TRANSPLANTATION |
| Artículo | 2014 | Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2014 | Single nucleotide polymorphisms (SNPS) in interleukin 1A and 1B genes associate with patient susceptibility to complications after HLA-identical sibling allo-SCT. | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2014 | SNPs in the promoter region of the IL17A gene allow anticipation of complications after sibling HLA-identical allogeneic stem cell transplantation (allo-SCT) | BONE MARROW TRANSPLANTATION |
| Artículo | 2013 | A variant in IRF3 impacts on the clinical outcome of AML patients submitted to Allo-SCT | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2013 | GSTT1 mismatch constitutes a risk factor for acute and chronic hepatic GVHD and influences patient survival | BONE MARROW TRANSPLANTATION |
| Artículo | 2013 | Intravenous ribavirin for respiratory syncytial viral infections in pediatric hematopoietic SCT recipients | BONE MARROW TRANSPLANTATION |
| Ponencia | 2013 | Onco-haematologic patients' sexuality. What do you do? What do you know about it? | BONE MARROW TRANSPLANTATION |
| Artículo | 2012 | A constitutional variant in the transcription factor EP300 strongly influences the clinical outcome of patients submitted to allo-SCT | BONE MARROW TRANSPLANTATION |
| Ponencia | 2012 | Central venous catheter-associated nosocomial infection | BONE MARROW TRANSPLANTATION |
| Artículo | 2012 | Incidence, characteristics and risk factors of marked hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning | BONE MARROW TRANSPLANTATION |
| Artículo | 2012 | Long-term follow-up of HCV-infected hematopoietic SCT patients and effects of antiviral therapy | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2012 | To freeze or not to freeze haematopoietic stem cells prior to allogeneic transplantation | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2011 | A new nursing intervention in NIC taxonomy: infusion of haematopoietic stem cells | BONE MARROW TRANSPLANTATION |
| Letter | 2011 | Drug rash with eosinophilia and systemic symptoms (DRESS) after an unrelated donor BM transplant | BONE MARROW TRANSPLANTATION |
| Letter | 2011 | Effect of vitamin D treatment in chronic GVHD | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2011 | Outcome of pandemic H1N1 infections in haematopoietic stem cell transplant recipients | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2011 | The presence of allele G in the donor for the polymorphism A7488G of the IL-17 gene improves relapse rate and survival after HLA-identical related stem cell transplantation | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2010 | Comparison between lymphoglobulin- and thymoglobulin-based immunosuppressive therapy as first-line treatment for patients with aplastic anaemia | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2010 | Constitutional variability in genes involved in innate immunity (IRF-3, HAMP, PTX3) and in cell proliferation (ATBF1 and NFAT5) influences disease free survival after allogeneic stem cell transplantation | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2010 | Differences in cytomegalovirus replication quantified by quantitative PCR and antigenemia pp-65 after allogeneic stem cell transplantation with different prevention strategies | BONE MARROW TRANSPLANTATION |
| Artículo | 2010 | Empirical antifungal therapy in selected patients with persistent febrile neutropenia | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2010 | Genetic mismatch in GSTT1 is associated with hepatic acute graft-versus-host disease in allogeneic stem cell transplantation | BONE MARROW TRANSPLANTATION |
| Letter | 2010 | Glutathione S-transferase T1 is a potential new target for the hepatic component of graft vs host disease after HSCT | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2010 | How organizational pre-transplant measures may improve clinical outcomes in haemopoietic stem cell transplantation | BONE MARROW TRANSPLANTATION |
| Ponencia | 2010 | Indication of empirical antifungal therapy in selected patients with persistent febrile neutropenia according to clinical criteria and risk profile | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2010 | Long-term follow-up of autologous stem cell transplant in AIDS-related Lymphoma patients. Results of Spanish Cooperative Registry GELTAMO/GESIDA | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2010 | Minimal residual disease post-consolidation therapy affects outcome after stem cell transplantation in acute myeloid leukaemia | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2010 | Pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation guided by quantitative real time-PCR | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2010 | Retrospective analysis of second haematopoietic stem cell transplant. Single-centre experience | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2009 | Association of CXCL12, VCAM1 and CD34 gene polymorphisms with peripheral blood progenitor cell mobilisation in healthy donors | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2009 | Catheter-related infections in tunnelled central venous devices in haematologic malignancies and haematopoietic stem cell transplantation patients. A single-centre experience | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2009 | Hickman catheter-associated infections after haematopoietic stem cell transplantation and their relationship with period elapsing from catheter implantation to transplantation | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2009 | Predictive factors for relapse in adult patients with high-risk acute lymphoblastic leukaemia submitted to an unrelated haematopoietic progenitor transplant | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2009 | Reasons why acute leukaemia patients with established indication for stem cell transplantation do not finally undergo the procedure and its clinical consequences | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2009 | Results of reduced-intensity conditioning stem cell transplantation with intensified fludarabine-based regimen for advanced lymphoid malignancies | BONE MARROW TRANSPLANTATION |
| Ponencia | 2008 | Preliminary descriptive analysis of the EBMT-TBI database: basis for future studies on the impact of TBI on the outcomes | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2008 | The efficacy of a single dose pegfilgrastim following myeloablative chemotherapy for stem cell mobilisation in patients with solid tumours and lymphomas | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2008 | The role of reduced-intensity allogeneic stem cell transplantation in patients with advanced acute myeloid leukaemia and myelodysplastic syndromes | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2007 | The role of allogeneic stem cell transplantation with reduced-intensity conditioning in patients with chemoresistant malignancies | BONE MARROW TRANSPLANTATION |
| Ponencia | 2006 | 1996-2006: ten years of EBMT-TBI registry data | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2006 | Epidemiology of cytomegalovirus in allogeneic haematopoietic stem cell transplant recipients | BONE MARROW TRANSPLANTATION |
| Artículo | 2006 | G-CSF increases the number of peripheral blood dendritic cells CD16+and modifies the expression of the costimulatory molecule CD86+ | BONE MARROW TRANSPLANTATION |
| Artículo | 2006 | Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2006 | Readmissions evaluation in allogeneic haematopoietic stem cell transplant recipients | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2006 | Risk for infection;: a daily battle against germs | BONE MARROW TRANSPLANTATION |
| Letter | 2006 | Vincristine is an effective therapeutic approach for transplantation-associated thrombotic microangiopathy | BONE MARROW TRANSPLANTATION |
| Ponencia | 2005 | Current state of the tbi registry 2004 | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2005 | Cyclosporine and methotrexate immunosuppression based regimen after non-myeloablative haematopoietic stem cell transplantation. Single-centre experience | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2005 | Rapamycine (Sirolimus) as salvage therapy for chronic graft-versus-host disease | BONE MARROW TRANSPLANTATION |
| Artículo | 2004 | Antibiotic prophylaxis with meropenem after allogeneic stem cell transplantation | BONE MARROW TRANSPLANTATION |
| Artículo | 2004 | Effect of cumulative etoposide doses on the outcome of autologous peripheral-blood progenitor-cell transplantation for lymphoma | BONE MARROW TRANSPLANTATION |
| Artículo | 2004 | Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results from the Spanish multicenter prospective trial | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2004 | HLA-DPB1 mismatch is associated with acute GvHD after HLA-identical sibling donor stem cell transplantation | BONE MARROW TRANSPLANTATION |
| Letter | 2004 | Prophylactic meropenem during neutropenia in allogeneic stem cell transplant recipients - Reply | BONE MARROW TRANSPLANTATION |
| Artículo | 2004 | Quality of life assessment in patients undergoing reduced intensity conditioning allogeneic as compared to autologous transplantation: results of a prospective study | BONE MARROW TRANSPLANTATION |
| Artículo | 2004 | QUALITY OF LIFE ASSESSMENT IN PATIENTS UNDERGOING REDUCED INTENSITY CONDITIONING ALLOGENEIC VS AUTOLOGOUS TRANSPLANTATION: RESULTS OF A PROSPECTIVE STUDY | BONE MARROW TRANSPLANTATION |
| Artículo | 2004 | REPLY ON BEHALF OF THE AUTHORS. | BONE MARROW TRANSPLANTATION |
| Artículo | 2004 | RESULTS AFTER AUTOLOGOUS LYMPHOMA TRANSPLANTATION ARE NOT IMPROVED BY INCREASING THE DOSE OF ETOPOSIDE IN THE BEAM REGIMEN: A SINGLE-CENTRE SEQUENTIAL COHORT STUDY. | BONE MARROW TRANSPLANTATION |
| Artículo | 2004 | Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study | BONE MARROW TRANSPLANTATION |
| Artículo | 2004 | Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections | BONE MARROW TRANSPLANTATION |
| Artículo | 2003 | Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2003 | Hemopoietic stem cell transplantation in childhood: improved survival over the years and reduction of transplant-related mortality in the autologous setting | BONE MARROW TRANSPLANTATION |
| Ponencia | 2003 | Influence of TBI in the appearance of late effects | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2002 | Phase I/II trials of autologous peripheral blood stem cell transplantation (ASCT) in autoimmune diseases (AID) resistant to conventional therapy: preliminary results of the Spanish experience | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2002 | Risk factors for acute graft-versus-host disease in patients transplanted with CD34+selected blood cells from HLA-identical siblings | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2001 | Allogeneic peripheral blood stem cell transplantation (allo-PBT): results of 327 patients from the Spanish registry. | BONE MARROW TRANSPLANTATION |
| Artículo | 2001 | Allogeneic transplantation of CD34(+)-selected cells from peripheral blood in patients with myeloid malignancies in early phase: a case control comparison with unmodified peripheral blood transplantation | BONE MARROW TRANSPLANTATION |
| Artículo | 2001 | Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 2001 | Variables affecting the collection of a CD34+cell dose > 4 x106/kg in healthy donors with one apheresis | BONE MARROW TRANSPLANTATION |
| Ponencia | 2000 | Current sate of the EBMT-TBI registry (1999) | BONE MARROW TRANSPLANTATION |
| Artículo | 2000 | Intra-muscular vidarabine therapy for polyomavirus-associated hemorrhagic cystitis following allogeneic hemopoietic stem cell transplantation | BONE MARROW TRANSPLANTATION |
| Artículo | 2000 | Successful treatment of severe hemorrhagic cystitis with cystectomy following matched donor allogeneic hematopoietic cell transplantation | BONE MARROW TRANSPLANTATION |
| Artículo | 1999 | Administration of recombinant human granulocyte colony-stimulating factor to normal donors: results of the Spanish National Donor Registry | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 1999 | Allogeneic vs autologous haemopoietic stem cell transplant (HSCT) in acute leukaemia (AL). | BONE MARROW TRANSPLANTATION |
| Artículo | 1999 | Clinical significance of CD34(+) cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 1999 | Comparative study of filgrastim and lenograstim for peripheral blood stem cell mobilization in healthy donors | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 1999 | Mixed chimerism detected by VNTR-PCR is associated with a high incidence of relapse after selective CD4+ depletion plus adjusted CD8+ T-cell content in BMT | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 1998 | Allogeneic peripheral blood progenitor cell transplantation (allo-PBT) in 64 patients with advanced hematologic malignancies. | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 1998 | Allogeneic peripheral blood progenitor cells transplantation (allo-PBT) in 64 patients with advanced hematologic malignancies. | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 1998 | Early infections in 163 consecutive autologous hemopoietic progenitor cell transplants. | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 1998 | Effects of granulocyte-colony stimulating factor in normal donors. Results of the Spanish National Donor Registry. | BONE MARROW TRANSPLANTATION |
| Resumen congreso | 1998 | Transplantation with peripheral blood stem cells from unrelated donor in chronic myelocytic leukaemia. | BONE MARROW TRANSPLANTATION |
| Artículo | 1997 | A single, double lumen high-flow catheter for patients undergoing peripheral blood stem cell transplantation. Experience at the National Cancer Institute in Mexico | BONE MARROW TRANSPLANTATION |
| Artículo | 1995 | Reversal of severe hepatic veno-occlusive disease by combined plasma exchange and rt-PA treatment | BONE MARROW TRANSPLANTATION |
| Nota | 1995 | REVERSAL OF SEVERE HEPATIC VENOOCCLUSIVE DISEASE BY COMBINED PLASMA-EXCHANGE AND RT-PA TREATMENT | BONE MARROW TRANSPLANTATION |
| Artículo | 1990 | PERIPHERAL BLOOD STEM CELL COLLECTION: COMPARISON OF TWO PROTOCOLS | BONE MARROW TRANSPLANTATION |
| Artículo | 1990 | PERIPHERAL-BLOOD STEM-CELL COLLECTION - COMPARISON OF 2 PROTOCOLS | BONE MARROW TRANSPLANTATION |
